【摘要】 目的探讨糖尿病肾病(DN)与血清单核细胞趋化蛋白1(MCP-l)、可溶性细胞间黏附分子1(sICAM-l)的相关性,以及辛伐他汀干预治疗对早期DN的作用。方法将60例DN患者随机分为对照组和辛伐他汀治疗组,治疗16周后,观察两组血清MCP-l、sICAM-l及尿白蛋白排泄率(UAER)变化,评价辛伐他汀对患者肾脏的保护作用。结果与对照组比较,治疗组血清MCP-1、sICAM-1及UAER均明显降低(P均<0.05)。结论辛伐他汀对早期DN患者有肾脏保护作用,能延缓其进展为终末期肾病。更多还原

【Abstract】 Objective To research the dependability between blood serum MCP-l and SICAM-l level and diabetes nephropathy relevance.Methods 60 diabetes nephropathy patients were divided into control groups and simvastatin treatment group randomly.After 16-week treatment,urine albumin excretion rate and MCP-l,SICAM-l level changes were observed,and renal protective effect of simvastatin was evaluated.Results Serum MCP-1,SICAM-1 and UAER levels in treatment group were significantly lower than control group(P<0.05).Conclusions Simvastatin can protect the kidney,and delay the progression of early diabetic nephropathy.更多还原